MassBiologics to open new research building in Boston
State-of-the-art laboratories designed to foster collaboration and
speed the pace of discovery
May 19, 2010
Launching the next phase of its century-old mission of protecting public health, MassBiologics at the University of Massachusetts Medical School will cut the ribbon tomorrow on a new $70-million research center on its Mattapan campus in Boston.
The 90,000-square-foot facility will centralize MassBiologics’ research and development team into state-of-the-art laboratories designed to foster collaboration and speed the pace of discovery.
“This is the beginning of a new era in research and discovery for MassBiologics,” said Donna Ambrosino, MD, executive director of MassBiologics and a professor of pediatrics at the Medical School. “This new facility will allow us to enhance and expand our research and bring new products to the public to address important, un-met medical needs.”
Construction of the research building began in September 2008, adjacent to MassBiologics’ manufacturing facility, which opened in Mattapan in 2005. The new building was designed with sustainability and energy efficiency in mind to align with the goals of Governor Deval Patrick’s Executive Order 484 “Leading By Example—Clean Energy and Efficient Buildings” and the American College & University Presidents Climate Commitment, signed in 2007 by UMass President Jack Wilson.
The opening ceremony is set for Thursday, May 20, at 1 p.m. Speaking at the event, in addition to Dr. Ambrosino, will be UMMS Chancellor Michael F. Collins, Larry Anderson, director of the Division of Viral Diseases at the National Center of Immunization and Respiratory Diseases at the U.S. Center for Disease Control and Prevention, and Subhash Kapre, executive director of the Serum Institute of India, a global leader in vaccine production and MassBiologics’ partner in an ongoing program to develop a monoclonal antibody to prevent rabies.
MassBiologics is the only non-profit, FDA-licensed manufacturer of vaccines and other biologic products in the United States. MassBiologics traces its roots to 1894, when it was created by the Massachusetts State Board of Health to produce diphtheria antitoxin. Since then, the laboratory has maintained a mission to improve public health through applied research, development and production of biologic products. MassBiologics became part of UMass Medical School in 1997.